Table 1.
Baseline and demographic characteristics
| Placebo group (n=54) | pGM169/GL67A group (n=62) | ||
|---|---|---|---|
| Age (years) | 26·0 (13·0) | 23·6 (10·8) | |
| <18 years old | 17 (31%) | 23 (37%) | |
| ≥18 years old | 37 (69%) | 39 (63%) | |
| Sex | |||
| Female | 25 (46%) | 31 (50%) | |
| Male | 29 (54%) | 31 (50%) | |
| Centre distribution number | |||
| Edinburgh | 24 (44%) | 22 (35%) | |
| London | 30 (56%) | 40 (65%) | |
| Height (cm) | 165·0 (10·6) | 163·6 (10·9) | |
| Weight (kg) | 61·6 (15·6) | 61·0 (15·7) | |
| FEV1 (% predicted) | 69·0 (9·9) | 69·9 (11·1) | |
| Body-mass index (kg/m2) | 22·4 (4·4) | 22·4 (4·5) | |
| Mutation class | |||
| Phe508del/Phe508del | 26 (48%) | 31 (50%) | |
| Phe508del/class 1–6 | 22 (41%) | 23 (37%) | |
| Not Phe508del/class 1 | 1 (2%) | 3 (5%) | |
| Heterozygous/homozygous class 3–6 | 2 (4%) | 2 (3%) | |
| Phe508del/unknown class | 3 (6%) | 3 (5%) | |
Data are mean (SD) or n (%), unless otherwise indicated.